300003 乐普医疗
已收盘 12-19 15:00:00
资讯
新帖
简况
乐普医疗最新公告：经导管植入式主动脉瓣膜系统获得NMPA注册批准
证券之星 · 12-17 18:49
乐普医疗最新公告：经导管植入式主动脉瓣膜系统获得NMPA注册批准
乐普医疗(300003.SZ)：经导管植入式主动脉瓣膜系统获注册批准
智通财经 · 12-17 18:41
乐普医疗(300003.SZ)：经导管植入式主动脉瓣膜系统获注册批准
乐普医疗新注册《乐普问诊系统V1.0》等17个项目的软件著作权
证券之星 · 12-01
乐普医疗新注册《乐普问诊系统V1.0》等17个项目的软件著作权
【港股通】心泰医疗(02291)盘初一度涨超50% 与乐普医疗续约即将到期的现有协议
金吾财讯 · 11-26
【港股通】心泰医疗(02291)盘初一度涨超50% 与乐普医疗续约即将到期的现有协议
港股异动 | 心泰医疗(02291)早盘拉升逾30% 近期与乐普医疗续约框架协议 未来三年交易额或逐年增加
智通财经 · 11-26
港股异动 | 心泰医疗(02291)早盘拉升逾30% 近期与乐普医疗续约框架协议 未来三年交易额或逐年增加
乐普医疗(300003.SZ)：MWN105注射液、MWN109注射液获药物临床试验批准
智通财经 · 11-25
乐普医疗(300003.SZ)：MWN105注射液、MWN109注射液获药物临床试验批准
概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线
格隆汇 · 11-17
概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线
华福证券：给予乐普医疗买入评级
证券之星 · 11-13
华福证券：给予乐普医疗买入评级
IPO雷达｜海金格闯关北交所，大客户乐普医疗兼任股东，保荐人中信建投突击入股
读创客户端 · 11-11
IPO雷达｜海金格闯关北交所，大客户乐普医疗兼任股东，保荐人中信建投突击入股
乐普医疗：业务调整、制剂去库存导致Q3短期承压 创新产品延续高增
国盛证券有限责... · 11-10
乐普医疗：业务调整、制剂去库存导致Q3短期承压 创新产品延续高增
华安证券：给予乐普医疗买入评级
证券之星 · 11-04
华安证券：给予乐普医疗买入评级
乐普医疗（300003）2024年三季报简析：净利润减40.7%，盈利能力上升
证券之星 · 10-27
乐普医疗（300003）2024年三季报简析：净利润减40.7%，盈利能力上升
乐普医疗(300003)9月30日股东户数9.4万户，较上期增加13.65%
证券之星 · 10-26
乐普医疗(300003)9月30日股东户数9.4万户，较上期增加13.65%
乐普医疗(300003.SZ)发布前三季度业绩，净利润8.03亿元，下降40.70%
智通财经 · 10-25
乐普医疗(300003.SZ)发布前三季度业绩，净利润8.03亿元，下降40.70%
南方电网旗下数研院辅导备案获受理，相宜本草、千叶眼镜终止辅导 | IPO
洞察IPO · 10-22
南方电网旗下数研院辅导备案获受理，相宜本草、千叶眼镜终止辅导 | IPO
乐普医疗最新公告：无创血糖仪获得NMPA注册批准
证券之星 · 10-15
乐普医疗最新公告：无创血糖仪获得NMPA注册批准
乐普医疗(300003.SZ)无创血糖仪获得NMPA注册批准
智通财经 · 10-15
乐普医疗(300003.SZ)无创血糖仪获得NMPA注册批准
10月8日乐普医疗涨16.63%，华宝中证医疗ETF基金重仓该股
证券之星 · 10-08
10月8日乐普医疗涨16.63%，华宝中证医疗ETF基金重仓该股
乐普医疗涨16.63%，中泰证券一个月前给出“买入”评级
证券之星 · 10-08
乐普医疗涨16.63%，中泰证券一个月前给出“买入”评级
乐普医疗最新公告：总经理张志斌、副总经理郑国锐因个人原因辞职
证券之星 · 09-25
乐普医疗最新公告：总经理张志斌、副总经理郑国锐因个人原因辞职
加载更多
公司概况
公司名称：
乐普(北京)医疗器械股份有限公司
所属行业：
专用设备制造业
上市日期：
2009-10-30
主营业务：
乐普(北京)医疗器械股份有限公司的主营业务是医疗器械、药品、医疗服务及健康管理。公司的主要产品是医疗器械、药品、医疗服务及健康管理。公司心血管医疗器械领域自主研发核心重磅产品，技术领先优势明显，尤其心血管领域“介入无植入”技术，引领中国甚至世界的行业发展；现有产品市场占有率继续稳健攀升，进一步扩大与竞争伙伴的领先地位。
发行价格：
29.00
{"stockData":{"symbol":"300003","market":"SZ","secType":"STK","nameCN":"乐普医疗","latestPrice":12.06,"timestamp":1734591798000,"preClose":12.18,"halted":0,"volume":14718132,"delay":0,"floatShares":1616000000,"shares":1880999999,"eps":0.3761,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.12,"latestTime":"12-19 15:00:00","open":12.08,"high":12.14,"low":11.91,"amount":177000000,"amplitude":0.0189,"askPrice":12.06,"askSize":312,"bidPrice":12.05,"bidSize":330,"shortable":0,"etf":0,"ttmEps":0.3761,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"adjPreClose":12.18,"symbolType":"stock","openAndCloseTimeList":[[1734571800000,1734579000000],[1734584400000,1734591600000]],"highLimit":13.4,"lowLimit":10.96,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1880610599,"pbRate":1.47,"roa":"--","roe":"5.01%","epsLYR":0.6757,"committee":-0.358707,"marketValue":22680000000,"floatMarketCap":19489000000,"peRate":32.06594,"changeRate":-0.0099,"turnoverRate":0.0091,"status":1},"requestUrl":"/m/hq/s/300003","defaultTab":"news","newsList":[{"id":"2492932709","title":"乐普医疗最新公告：经导管植入式主动脉瓣膜系统获得NMPA注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2492932709","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492932709?lang=zh_cn&edition=full","pubTime":"2024-12-17 18:49","pubTimestamp":1734432573,"startTime":"0","endTime":"0","summary":"乐普医疗公告，旗下子公司乐普心泰所属产品ScienCrown®经导管植入式主动脉瓣膜系统获得国家药品监督管理局（NMPA）注册批准，注册证编号为国械注准20243132550。该产品适用于经心脏团队评估后，需要接受主动脉瓣置换且不适合接受常规外科手术置换瓣膜的重度主动脉瓣钙化性狭窄患者。ScienCrown经导管植入式主动脉瓣膜系统结合已获批上市的ScienMelon®主动脉瓣膜球囊扩张导管，有望为临床提供更全面、可靠的一体化解决方案。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121700032500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0188","BK0196","300003","BK0201","BK0028","BK0113","BK0251","BK0114"],"gpt_icon":0},{"id":"2492932691","title":"乐普医疗(300003.SZ)：经导管植入式主动脉瓣膜系统获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2492932691","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492932691?lang=zh_cn&edition=full","pubTime":"2024-12-17 18:41","pubTimestamp":1734432083,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普医疗(300003.SZ)公告，公司旗下子公司乐普心泰所属产品ScienCrown®经导管植入式主动脉瓣膜系统获得国家药品监督管理局(NMPA)注册批准，乐普医疗作为医疗器械注册人。该产品适用范围为：适用于经心脏团队结合评分系统评估后认为患有有症状的、钙化的、重度退行性主动脉瓣狭窄，不适合接受常规外科手术置换瓣膜的年龄大于等于70岁的患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"乐普医疗(300003.SZ)：经导管植入式主动脉瓣膜系统获注册批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0042","BK0114","BK0196","BK0028","BK0188","BK0201","300003","BK0251","BK0113"],"gpt_icon":0},{"id":"2488650961","title":"乐普医疗新注册《乐普问诊系统V1.0》等17个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2488650961","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488650961?lang=zh_cn&edition=full","pubTime":"2024-12-01 01:17","pubTimestamp":1732987028,"startTime":"0","endTime":"0","summary":"今年以来乐普医疗新注册软件著作权19个。结合公司2024年中报财务数据，今年上半年公司在研发方面投入了3.56亿元，同比减19.28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120100000037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003","BK0201","BK0028","BK0114","BK0188","BK0113","BK0251","BK0042","BK0196"],"gpt_icon":0},{"id":"2486013223","title":"【港股通】心泰医疗(02291)盘初一度涨超50% 与乐普医疗续约即将到期的现有协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2486013223","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486013223?lang=zh_cn&edition=full","pubTime":"2024-11-26 10:59","pubTimestamp":1732589962,"startTime":"0","endTime":"0","summary":"金吾财讯 | 心泰医疗(02291)盘初一度涨超50%，截至发稿，涨21.15%，报20.45港元，成交额3290万港元。消息面上，日前公司发布公告，宣布与乐普医疗于2024年10月21日签署了委托产品相关框架协议，旨在续约即将到期的现有协议。根据新协议，心泰医疗将在2025年1月1日至2027年12月31日期间，购买乐普医疗生产的经导管植入式主动脉瓣膜系统，并获得其独家授权进行销售和经销。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948395","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCEI","BK0113","BK0042","BK0196","BK0114","02291","BK1100","BK0251","BK0028","YANG","BK0201","HSTECH","BK0188","300003","07226"],"gpt_icon":0},{"id":"2486113092","title":"港股异动 | 心泰医疗(02291)早盘拉升逾30% 近期与乐普医疗续约框架协议 未来三年交易额或逐年增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2486113092","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486113092?lang=zh_cn&edition=full","pubTime":"2024-11-26 10:02","pubTimestamp":1732586574,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，心泰医疗早盘拉升逾30%，截至发稿，涨30.92%，报22.1港元，成交额1956.13万港元。消息面上，心泰医疗发布公告，宣布与乐普医疗于2024年10月21日签署了委托产品相关框架协议，旨在续约即将到期的现有协议。根据新协议，心泰医疗将在2025年1月1日至2027年12月31日期间，购买乐普医疗生产的经导管植入式主动脉瓣膜系统，并获得其独家授权进行销售和经销。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0251","300003","BK0113","BK0042","BK0196","02291","BK0114","BK1100","BK0028","BK0201","BK0188"],"gpt_icon":0},{"id":"2486070448","title":"乐普医疗(300003.SZ)：MWN105注射液、MWN109注射液获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486070448","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486070448?lang=zh_cn&edition=full","pubTime":"2024-11-25 18:54","pubTimestamp":1732532092,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普医疗(300003.SZ)公告，公司控股子公司上海民为生物技术有限公司(简称“民为生物”)收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》，由民为生物申报的MWN109注射液、MWN105注射液临床试验申请获得批准。根据公告所示，MWN105注射液适应症为：超重或肥胖适应症、2型糖尿病;MWN109注射液适应症为：2型糖尿病、超重或肥胖适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0113","BK0188","BK0201","BK0196","BK1141","BK0114","03347","BK1583","BK0042","BK0251","BK1576","300003","BK0028"],"gpt_icon":0},{"id":"2484509265","title":"概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线","url":"https://stock-news.laohu8.com/highlight/detail?id=2484509265","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484509265?lang=zh_cn&edition=full","pubTime":"2024-11-17 14:35","pubTimestamp":1731825344,"startTime":"0","endTime":"0","summary":"市场前景广阔","market":"hk","thumbnail":"https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1336126","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU0154236417.USD","BK0132","603456","BK0196","LU1093756168.USD","688076","BK0114","BK4585","BK0201","BK0183","LU1064130708.USD","BK0028","LU1328615791.USD","01801","BK4007","LU1093756325.SGD","BK0239","300003","600276","BK0077","LU2488822045.USD","BK0060","BK0012","BK4532","BK0070","LU0405327148.USD","688117","IE00BKVL7J92.USD","BK0042","LU0405327494.USD","LU1064131003.USD","NVO","BK0113","002821","BK0188","IE00BZ1G4Q59.USD","300199","BK0251","LU2148510915.USD","BK4588"],"gpt_icon":1},{"id":"2483746080","title":"华福证券：给予乐普医疗买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2483746080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483746080?lang=zh_cn&edition=full","pubTime":"2024-11-13 18:30","pubTimestamp":1731493840,"startTime":"0","endTime":"0","summary":"华福证券有限责任公司陈铁林,王艳,刘佳琦近期对乐普医疗进行研究并发布了研究报告《药品板块渠道调整影响有望进入尾声，创新器械维持高增》，本报告对乐普医疗给出买入评级，当前股价为13.06元。考虑到公司创新器械加速放量，且药品板块渠道影响进入尾声，新制剂相继上市，后续有望实现药品业务平稳增长，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级7家；过去90天内机构目标均价为15.0。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111300030523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300003"],"gpt_icon":0},{"id":"2482222442","title":"IPO雷达｜海金格闯关北交所，大客户乐普医疗兼任股东，保荐人中信建投突击入股","url":"https://stock-news.laohu8.com/highlight/detail?id=2482222442","media":"读创客户端","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482222442?lang=zh_cn&edition=full","pubTime":"2024-11-11 14:32","pubTimestamp":1731306778,"startTime":"0","endTime":"0","summary":"大客户乐普医疗兼任股东股权方面，医药代表出身的齐学兵为海金格控股股东和实控人，合计控制股权比例为54.98%。在北交所首轮问询中，海金格被要求说明与乐普医疗相关交易的必要性和公允性、双方是否存在利益输送等情况。此次IPO，海金格的保荐机构正是中信建投。其中，2023年，海金格业绩增速明显放缓。另据天眼查网站，2022年9月，海金格被北京市公安局丰台分局罚款1万元，处罚事由为“非法聘用外国人”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111144128abb503a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111144128abb503a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0042","601066","BK0188","BK0196","BK0276","300003","BK0114","BK0028","BK0201","BK0113","BK0251"],"gpt_icon":0},{"id":"2482023059","title":"乐普医疗：业务调整、制剂去库存导致Q3短期承压 创新产品延续高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2482023059","media":"国盛证券有限责...","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482023059?lang=zh_cn&edition=full","pubTime":"2024-11-10 15:53","pubTimestamp":1731225236,"startTime":"0","endTime":"0","summary":"乐普医疗发布2024 年三季度报告。2024Q3，实现营业收入14.02 亿元，同比下滑28.41%；归母净利润1.05 亿元，同比下滑73.12%；扣非后归母净利润0.87 亿元，同比下滑77.19%。Q3 业绩增速继续放缓，主要系业务结构调整、制剂业务渠道库存清理等因素影响。制剂业务渠道去库存接近尾声，胰岛素产品顺利进院放量可期。药品板块短期承压主要系制剂业务渠道去库存影响，Q3 去库存接近尾声，发货端数据已实现逐月好转，Q4 有望迎来业绩改善。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110155358abb28705&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110155358abb28705&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0215","BK0251","BK0113","300003","BK0196","BK0188","000860","BK0201","BK0028","BK0042","BK0114","BK0195"],"gpt_icon":0},{"id":"2480622342","title":"华安证券：给予乐普医疗买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480622342","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480622342?lang=zh_cn&edition=full","pubTime":"2024-11-04 11:55","pubTimestamp":1730692518,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超,李婵近期对乐普医疗进行研究并发布了研究报告《2024Q3药品板块拖累业绩，归核聚焦再出发》，本报告对乐普医疗给出买入评级，当前股价为11.96元。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级6家；过去90天内机构目标均价为15.0。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400011422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600909","300003"],"gpt_icon":0},{"id":"2478843811","title":"乐普医疗（300003）2024年三季报简析：净利润减40.7%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2478843811","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478843811?lang=zh_cn&edition=full","pubTime":"2024-10-27 10:57","pubTimestamp":1729997861,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期乐普医疗发布2024年三季报。截至本报告期末，公司营业总收入47.85亿元，同比下降23.55%，归母净利润8.03亿元，同比下降40.7%。按单季度数据看，第三季度营业总收入14.02亿元，同比下降28.41%，第三季度归母净利润1.05亿元，同比下降73.12%。本报告期乐普医疗盈利能力上升，毛利率同比增幅5.1%，净利率同比增幅15.05%。去年的净利率为16.2%，算上全部成本后，公司产品或服务的附加值高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102700011265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003"],"gpt_icon":0},{"id":"2478942624","title":"乐普医疗(300003)9月30日股东户数9.4万户，较上期增加13.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478942624","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478942624?lang=zh_cn&edition=full","pubTime":"2024-10-26 17:02","pubTimestamp":1729933376,"startTime":"0","endTime":"0","summary":"证券之星消息，近日乐普医疗披露，截至2024年9月30日公司股东户数为9.4万户，较6月30日增加1.13万户，增幅为13.65%。在医疗器械行业个股中，乐普医疗股东户数高于行业平均水平，截至9月30日，医疗器械行业平均股东户数为2.02万户。从股价来看，2024年6月30日至2024年9月30日，乐普医疗区间跌幅为9.9%，在此期间股东户数增加1.13万户，增幅为13.65%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102600008526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0251","BK0188","BK0196","300003","BK0201","BK0042","BK0113","BK0028"],"gpt_icon":0},{"id":"2478987354","title":"乐普医疗(300003.SZ)发布前三季度业绩，净利润8.03亿元，下降40.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478987354","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478987354?lang=zh_cn&edition=full","pubTime":"2024-10-25 20:58","pubTimestamp":1729861126,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普医疗(300003.SZ)发布2024年三季度报告，该公司前三季度营业收入为47.85亿元，同比减少23.55%。归属于上市公司股东的净利润为8.03亿元，同比减少40.70%。归属于上市公司股东的扣除非经常性损益的净利润为7.34亿元，同比减少42.91%。基本每股收益为0.4339元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1200293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300003"],"gpt_icon":0},{"id":"2477334690","title":"南方电网旗下数研院辅导备案获受理，相宜本草、千叶眼镜终止辅导 | IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2477334690","media":"洞察IPO","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477334690?lang=zh_cn&edition=full","pubTime":"2024-10-22 20:38","pubTimestamp":1729600680,"startTime":"0","endTime":"0","summary":"南网数研院业务包括四大板块。据此估算，南网数研院估值约123.38亿元。目前，中国南方电网有限责任公司的全资子公司南方电网数字电网集团有限公司持有南网数研院74%股份，为其控股股东。2023年12月，南网数研院与海通证券签署上市辅导协议，进行了第一次辅导备案。此次辅导券商变更为招商证券。辅导备案终止10月15日-10月21日，15家公司境内发行上市辅导备案终止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2024-10-22/doc-inctmwyx4372821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0251","300003","BK0113","BK0196","BK0188","BK0201","BK0028","BK0042","BK0114"],"gpt_icon":0},{"id":"2475638878","title":"乐普医疗最新公告：无创血糖仪获得NMPA注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2475638878","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475638878?lang=zh_cn&edition=full","pubTime":"2024-10-15 22:51","pubTimestamp":1729003873,"startTime":"0","endTime":"0","summary":"乐普医疗公告，公司于今日获悉，公司自主研发的无创血糖仪正式获得国家药品监督管理局（NMPA）注册批准，以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101500037815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0251","BK0042","BK0201","BK0113","BK0028","BK0196","BK0188","300003"],"gpt_icon":0},{"id":"2475557283","title":"乐普医疗(300003.SZ)无创血糖仪获得NMPA注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2475557283","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475557283?lang=zh_cn&edition=full","pubTime":"2024-10-15 19:25","pubTimestamp":1728991537,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普医疗(300003.SZ)公告，公司于今日获悉，公司自主研发的无创血糖仪正式获得国家药品监督管理局(NMPA)注册批准，医疗器械注册证编号：国械注准20243072020。据悉，该产品可无创地估算成人体内葡萄糖浓度，使用前需要经指尖血糖校准后(需空腹血糖标定及餐后2小时血糖标定)，校准时间间隔不得超过30天，供非胰岛素治疗的2型糖尿病患者日常的自我血糖管理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1194369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0201","BK0113","300003","BK0251","BK0114","BK0188","BK0196","BK0042"],"gpt_icon":0},{"id":"2473118446","title":"10月8日乐普医疗涨16.63%，华宝中证医疗ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2473118446","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473118446?lang=zh_cn&edition=full","pubTime":"2024-10-08 17:34","pubTimestamp":1728380089,"startTime":"0","endTime":"0","summary":"证券之星消息，10月8日乐普医疗涨16.63%创60日新高，收盘报15.36元，换手率7.9%，成交量127.68万手，成交额19.13亿元。根据2024基金半年报公募基金重仓股数据，重仓该股的公募基金共45家，其中持有数量最多的公募基金为华宝中证医疗ETF。华宝中证医疗ETF目前规模为217.6亿元，最新净值0.3645，较上一交易日上涨13.41%，近一年下跌12.3%。华宝中证医疗ETF的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100800026309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159828","BK0113","300003","BK0188","BK0251","512170","BK0201","BK0196","BK0028","BK0042","BK0114"],"gpt_icon":0},{"id":"2473446937","title":"乐普医疗涨16.63%，中泰证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2473446937","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473446937?lang=zh_cn&edition=full","pubTime":"2024-10-08 17:34","pubTimestamp":1728380084,"startTime":"0","endTime":"0","summary":"今日乐普医疗（300003）涨16.63%，收盘报15.36元。2024年8月27日，中泰证券研究员祝嘉琦,谢木青,于佳喜发布了对乐普医疗的研报《创新器械产品持续表现亮眼，政策扰动下业绩整体稳健》，该研报对乐普医疗给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为52.38%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为东方财富证券的何玮。乐普医疗（300003）个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100800026305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003","600918"],"gpt_icon":0},{"id":"2470256715","title":"乐普医疗最新公告：总经理张志斌、副总经理郑国锐因个人原因辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2470256715","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470256715?lang=zh_cn&edition=full","pubTime":"2024-09-25 20:11","pubTimestamp":1727266276,"startTime":"0","endTime":"0","summary":"乐普医疗公告，公司董事会于近日收到公司总经理张志斌、副总经理郑国锐递交的辞职报告，因个人原因申请辞去公司现任职务，辞职后将不再担任公司任何职务。公司于2024年9月24日召开第六届董事会第十一次会议，审议通过了《关于聘任公司总经理的议案》，同意聘任蒲绯为公司总经理，任期自本次董事会审议通过之日起至第六届董事会届满之日止。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092500031982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0114","300003","BK0201","BK0196","BK0251","BK0042","BK0113","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-10-30","address":"北京市昌平区超前路37号","stockEarnings":[{"period":"1week","weight":-0.0274},{"period":"1month","weight":-0.0258},{"period":"3month","weight":0.3282},{"period":"6month","weight":-0.2068},{"period":"1year","weight":-0.2108},{"period":"ytd","weight":-0.2255}],"companyName":"乐普(北京)医疗器械股份有限公司","boardCode":"AI0035","perCapita":"17191股","boardName":"专用设备制造业","registeredCapital":"188061万元","compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":0.0072},{"period":"3month","weight":0.2314},{"period":"6month","weight":0.124},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1328}],"survey":" 乐普(北京)医疗器械股份有限公司的主营业务是医疗器械、药品、医疗服务及健康管理。公司的主要产品是医疗器械、药品、医疗服务及健康管理。公司心血管医疗器械领域自主研发核心重磅产品，技术领先优势明显，尤其心血管领域“介入无植入”技术，引领中国甚至世界的行业发展；现有产品市场占有率继续稳健攀升，进一步扩大与竞争伙伴的领先地位。","serverTime":1734633886018,"listedPrice":29,"stockholders":"94003人(较上一季度增加13.65%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"乐普医疗(300003)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供乐普医疗(300003)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"乐普医疗,300003,乐普医疗股票,乐普医疗股票老虎,乐普医疗股票老虎国际,乐普医疗行情,乐普医疗股票行情,乐普医疗股价,乐普医疗股市,乐普医疗股票价格,乐普医疗股票交易,乐普医疗股票购买,乐普医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"乐普医疗(300003)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供乐普医疗(300003)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}